
Opinion|Videos|November 4, 2024
Future Perspective on Anemia Treatment in LR-MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, explores the future treatment landscape for anemia in lower-risk myelodysplastic syndromes (LR-MDS), discussing the impact of emerging therapies on erythropoietin-stimulating agents (ESAs), identifying unmet needs in anemia management, and sharing clinical insights for community oncologists.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?
- What are the current unmet needs in the treatment of anemia in LR-MDS?
- What clinical pearls could you share to community oncologists in the treatment of anemia for patients with LR-MDS?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























